Begin What the term means
A peptide is a tiny chain. Its name alone cannot tell you whether a treatment suits you.
Start with the exact name of the proposed medicine and the problem it is meant to treat.
Peptides are small chains of protein building blocks.
These building blocks are called amino acids. They also join together to make proteins.
Insulin is a peptide, too.
The word alone cannot tell you whether a proposed treatment fits your goal.
FDA approval is for one named medicine and use.
As of September 2026, FDA-approved U.S. medicines included semaglutide under the brand names Wegovy and Ozempic, plus tirzepatide under the brand names Zepbound and Mounjaro.
The agency that reviews medicines for the United States is the Food and Drug Administration, known by the initials FDA.
An FDA approval covers a specific medicine and its intended use; similar names do not extend that approval to other products.
Ask the person prescribing your medicine for its exact name and what it would treat.
A compounded medicine is made to order.
Compounding is making or changing a medicine for a patient, often at a pharmacy.
As of September 2026, FDA had not approved medicines prepared to order. FDA did not check how well they were made, whether they worked or their safety before sale.
A medicine made to order can help when no approved medicine can meet a patient’s need. As of September 2026, the pharmacy still had to meet the rules for making it.
For a regular pharmacy, the rules include a valid prescription for one named patient.
A regular pharmacy cannot routinely make almost the same medicine as one already sold by a drug company.
One exception is a change the person prescribing it decides makes a significant difference for that particular patient.
The pharmacy must also meet the ingredient rules that apply to it.
A familiar research name does not settle the question.
As of September 2026, neither BPC-157 nor ipamorelin had an FDA-approved U.S. drug product.
FDA approval and permission for a pharmacy to make a medicine are different checks.
As of September 2026, FDA records showed BPC-157 did not meet the ingredient rules for a regular pharmacy making medicine for one named patient.
FDA also listed concerns about the safety of BPC-157 and ipamorelin acetate, the form of ipamorelin on that list.
Ask the person prescribing it which medicine is proposed, what evidence supports it and which rules allow the pharmacy to make it.
Footnotes for this page
- A
Calling something a “peptide” describes its building pieces. That name alone cannot establish whether it can legally be supplied as medicine.
FDA · Questions about compoundingFDA · Understanding approval - B
Check the FDA record for the named medicine and the use being offered. Approval of one medicine does not approve all peptide care.
FDA · Understanding approvalFDA · Semaglutide product informationFDA · Tirzepatide product information - C
Preparing a medicine to order may address a patient’s need, but FDA has not approved it. Rules also limit making versions of medicines already sold by drug companies.
FDA · Questions about compoundingFDA · Compounding and national supply - D
FDA records showed no U.S. drug approval for BPC-157 or ipamorelin. Ask which ingredient rule the pharmacy is relying on.
FDA · Drug-approval application recordsFDA · Concerns about peptide ingredients
